
Atossa Therapeutics fell 83.6% from $11.78 to $1.93, behind the S&P 500's +11.2%. Its worst day was Jun 11 (−41.3%), and its low came Jun 24 at $1.75.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Atossa Therapeutics closed at its highest level of the year, 15.3% above where the year started.
+6.4% · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
Atossa Therapeutics shares fell 34.0%, while the S&P 500 rose 0.5%.
−34.0% · S&P 500 +0.5%
Atossa Therapeutics shares fell 16.0%, while the S&P 500 fell 0.0%.
−16.0% · S&P 500 0.0%
EPS of $-0.03 beat the $-1.11 estimate on $0.00 revenue.
−13.1% · S&P 500 −1.8%
EPS of $-1.11 beat the $-1.22 estimate on $0.00 revenue.
−1.2% · S&P 500 +0.8%
Atossa Therapeutics shares fell 41.3%, while the S&P 500 rose 1.7%.
−41.3%, the year's worst day, on 1M shares, the year's heaviest volume · S&P 500 +1.7%
Atossa Therapeutics closed at its lowest level of the year, 85.1% below where the year started.
−7.9% · S&P 500 0.0%
EPS of $-0.95 beat the $-1.09 estimate on $0.00 revenue.
−2.5% · S&P 500 +0.6%
Atossa Therapeutics shares rose 16.4%, while the S&P 500 rose 0.2%.
+16.4%, the year's best day · S&P 500 +0.2%
EPS of $-0.56 beat the $-0.80 estimate on $0.00 revenue.
+0.5% · S&P 500 −0.4%
Where it ended: a close of $1.93 on Nov 16, 2026.
Nothing in the past 12 months.
All ATOS dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ATOS and SPY from Benzinga historical bars. Not investment advice.